News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
TradingView Guidance
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Sirenia Capital Management LP and Alex Silverstein have reported a beneficial ownership of 3,029,500 Common Shares in Cybin Inc., which includes 969,500 shares issuable upon the exercise of warrants. This stake represents 4.8% of Cybin's outstanding Common Shares, based on 61,984,078 shares as of …
Cybin Inc., doing business as Helus Pharma, has released its unaudited condensed interim consolidated financial statements for the first quarter ended June 30, 2026. The company reported a net loss of $47,819 thousand for the period, compared to a net loss of $24,613 thousand …
* Cybin press release [https://seekingalpha.com/pr/20619592-helus-pharma-reports-first-quarter-fiscal-2027-financial-results-and-recent-business] (HELP [https://seekingalpha.com/symbol/HELP]): Q1 Net loss was $47.8 million for the quarter ended June 30, 2026, compared to a net loss of $24.6 million in the same period last year. * Cash totaled $166.4 million as of June 30, 2026. …
Cybin, Inc. (CN:HELP) shares saw a significant 7.45% surge on August 12, 2026, driven by increased trading activity, though the exact catalyst remains unconfirmed. The clinical-stage biopharmaceutical company focuses on developing psychedelic-based therapies for mental health conditions like depression. Investors are advised to research …
Adage Capital Management, L.P. and associated parties have disclosed a 5.29% beneficial ownership in Cybin Inc. (HELP), totaling 3,289,250 common shares, which includes shares issuable from warrants. This ownership stake grants them shared voting and dispositive power over these shares. The filing, a Schedule …
Cybin Inc. (CN:HELP), a clinical-stage biotechnology company focused on psychedelic-based therapeutics for mental health, saw its shares decline by 14.05% on August 10, 2026, due to cautious investor sentiment in the emerging healthcare sector. The company's business model relies on R&D and clinical advancement, …
Helus Pharma (Cybin Inc.) CEO Michael Halstead will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026, at 12:00 p.m. EDT. The clinical-stage pharmaceutical company is developing novel serotonergic agonists (NSAs) for mental health conditions, including …
Helus Pharma (Nasdaq: HELP) will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11-12, 2026. CEO Michael Halstead is scheduled to present in a fireside chat on Wednesday, August 12, at 12:00 p.m. EDT. The company, known for developing …
Cybin Inc. (CN:HELP) shares dropped by 10.54% due to investor caution surrounding psychedelic medicine, regulatory uncertainties, and the inherent volatility of clinical-stage biotechnology companies. The company develops psychedelic-based therapies for mental health, but its valuation is highly dependent on successful clinical trials, regulatory approvals, …
This article provides an earnings forecast for CISO Global Inc (CISO), including future EPS and revenue growth estimates. It notes the company's current stock price, market cap, and P/E ratio, along with a list of peer companies for comparison. The financial data was updated …
Cybin (HELP) has appointed Michael Halstead as its new CEO, leading to significant short-term share price momentum with a 48.47% return over 7 days and 118.64% over 90 days, despite a long-term decline. A Simply Wall St. narrative suggests the stock is 69.1% undervalued …
This page provides current stock news for Mainz Biomed N V Ord Shs (QUCY), including its stock price, market cap, and links to financial data, analyst ratings, and ownership information. As of the latest update, the stock was trading at $1.440, up 4.35%. The …
Cybin Inc, now operating as Helus Pharma (CN:HELP), saw its stock rally 4.62% to C$15.40 with high relative volume, following a new CEO appointment on August 3, 2026, and the early completion of Phase 3 trial enrollment on July 21, 2026. While no specific …
Helus Pharma appointed Michael Halstead as CEO, a move that could significantly influence Cybin's strategic direction. Halstead's extensive experience in commercialization and M&A in the biopharma sector may reshape how Cybin approaches growth, partnerships, and capital allocation, especially as it moves towards potential commercialization …
Cybin's stock (HELP) surged 33.1% after appointing Michael Halstead, a veteran from Helus Pharma, as its new CEO. Halstead brings 25 years of biopharma experience, including significant roles in acquisitions and commercialization of psychiatric drugs, which could transform Cybin's late-stage development. While this appointment …
Helus Pharma (formerly Cybin, stock symbol HELP) saw its shares jump 14.02% ahead of crucial Phase 3 trial data for its lead depression drug, HLP003, expected in Q4 2026. The company recently appointed a new CEO and completed trial enrollment ahead of schedule, with …
Helus Pharma (Nasdaq: HELP) has appointed Michael Halstead, former President of Intra-Cellular Therapies, as CEO, effective immediately. This strategic move comes months before the company's pivotal Phase 3 data readout for HLP003, a novel serotonergic agonist for Major Depressive Disorder (MDD) which has received …
Shares of Cybin Inc. (HELP), a clinical-stage biopharmaceutical company focused on psychedelic-based treatments, rose over 13% on Wednesday. This continued a rally initiated by the announcement of Michael Halstead's appointment as CEO. The article also briefly discusses potential impacts of the CEO change on …
Helus Pharma (operating as Cybin Inc.) has appointed Michael Halstead as its new Chief Executive Officer, effective immediately. This appointment comes as the company advances its HLP003 program into Phase 3 for Major Depressive Disorder, with topline data expected in Q4 2026, and HLP004 …
Cybin Inc. published a corporate presentation detailing the development of its serotonergic agonists. The presentation highlights HLP003, an oral drug in Phase 3 for major depressive disorder with FDA Breakthrough Therapy Designation, targeting topline data for Q4 2026. Additionally, HLP004, an intramuscular drug for …
This article provides a technical analysis of CISO Global Inc (CISO), detailing its current price momentum score, support and resistance levels, and performance based on various technical indicators and moving averages. It highlights that CISO is suitable for range-bound swing trading, with its price …
CISO Global Inc. (CISO) is trading at $0.256, showing a slight increase of 1.63%. The company, which specializes in cybersecurity, compliance, and software, has experienced significant price declines over the past year. Despite its growth phase and high institutional ownership, its stock is considered …
CISO Global Inc (CISO) has a weak financial status and average operating efficiency, ranking 419 out of 485 in its industry. The company's latest quarterly revenue decreased by 13.15% year-over-year, while its net profit saw a 70.03% year-over-year decrease. Its current financial score is …
Search by ticker symbol or company name and select a result to open its chart.